Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
45 results about "Basal insulin" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Basal insulin is a crucial component in your diabetes management. Work with your doctor or endocrinologist to determine which type is best for you and your needs.
A method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (PWD). The method may also include modifying the baseline basal insulin rate stored in the memory for a second diurnal time period that is at least 20 hours after the first diurnal period based on an amount of insulin actually delivered during the first diurnal time period.
Exemplary embodiments may configure the glucose cost component of a cost function used in determining basal insulin delivery doses to be limited by the maximum physiological rate of glucose level change over a time period so that the cost function more accurately reflects the physical limits of change due to insulin action, As a result, the glucose cost component of the cost function may more accurately reflect the response of a user to basal insulin deliveries, resulting in better insulin control for the user. Exemplary embodiments may modify the aggressiveness of a control approach based on a current target glucose level versus a nominal target glucose level for which the control approach was designed.
A diabetes managementsystem adapted to determine adherence for a subject in treatment according to a basal insulinregimen, the system being adapted to receive regimen data. BG data and insulin injection data. If one or more insulin injections have not been received in accordance with the prescribed regimen and thus are missing, the system is adapted to calculate for each missing injection an expected dose response BG value. By comparing received BG data, corresponding to the missing insulin injections, it can be determined for a given confidence interval whether or not the subject has been in adherence with the basal insulin regimen.
TITLE OF THE INVENTION: DEVICE FOR DYNAMIC DETERMINATION OF BASAL INSULINDOSE TO BE INJECTED The device for dynamically determining the dose of basal insulin to be injected comprises: - a means (21) for capturing a blood glucose level at bedtime one day and a blood glucose level upon waking the following morning, - a means (26) for calculating the difference between blood glucose levels, - a means (22, 24, 25, 42, 43) for determining whether a predetermined event has occurred between bedtime and waking, - a means (26) for determining, if no predetermined event has occurred, hyperglycemia or hypoglycemia based on the difference between blood glucose levels, - a means (26) for determining whether at least a predetermined number of hyperglycemic or hypoglycemic episodes have occurred within a predetermined period of time, and - a means (26) for modifying the basal insulin to be injected, in this case of occurrence. Figure for the abbreviation: Figure 1.
A system for determining a deficiency in an infusion rate for a user has a processor, a display, a memory and, optionally, one or more of a pump and an analyte monitor. The processor receives measured glucose values that each have a timestamp indicating the time / date of measurement. The processor determines whether the glucose values include n pairs of glucose values g01 to n and g1to n, where each pair of glucose values fulfils a predefined set of criteria obtained from the memory. Pairing values are determined based on the glucose values g0x and g1x. The pairing values are compared to threshold values obtained from the memory. Exceeding or falling below the threshold values indicates a deficiency of the basal insulin rate of the patient.
A diabetes managementsystem adapted to determine compliance of a subject in treatment according to a basal insulinregimen, the system adapted to receive regimen data, blood glucose data, and insulin injection data. If one or more insulin injections are not received in accordance with the specified regimen and thus missing, the system is adapted to calculate a predicted dose-responsive blood glucose level for each missing injection. By comparing the received blood glucose data corresponding to missing insulin injections, it may be determined whether the subject is compliant with the basal insulin regimen for a given confidence interval.
An apparatus comprising a user interface configured to generate an electrical signal to start a basal insulin rate test when prompted by a user, an input configured to receive sampled blood glucose data of a patient that is obtained during a specified time duration, including a time duration during delivery of insulin according to a specified basal insulin rate pattern, and a controller communicatively coupled to the input and the user interface. The controller includes an insulin calculation module configured for determining at least one of an amount of basal insulin over-delivered and an amount of basal insulin under-delivered during the basal insulin rate test in trying to meet a target blood glucose baseline. Other devices and methods are disclosed.
Provided are a method, system, and computer-readable medium for personalizing titration measurement for basal insulin dosing. The personalization can be achieved using spare self-monitoring blood glucose (SMBG) and / or dense continuous glucose monitoring (CGM) data to predict a fasting blood glucose (FBG) envelope accounting for online estimation of titrationnoise representative of variability in daily fasting measurement. As a result, basal insulin dosing directed to causing the FBG envelope to be maintained for an optimal glycemic range can then be obtained.
A method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (PWD). The method may also include modifying the baseline basal insulin rate stored in the memory for a second diurnal time period that is at least 20 hours after the first diurnal period based on an amount of insulin actually delivered during the first diurnal time period.
A continuous glucose monitor (CGM)-driven basal insulintitrationsystem and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulindose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulindose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.
A system includes one or more processors and one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of obtaining an insulin-on-board (IOB) value, wherein the IOB value is a quantity of insulin remaining in a patient following delivery of a bolus of insulin, scaling a total daily dose (TDD) value by a factor, to generate a result having a value that is less than the TDD value, based on determining that the IOB value is greater than the result, identifying a condition in which the patient's glucose level will continue to decrease after suspension of basal insulin dosage delivery, and responsive to identifying the condition, causing performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.
Exemplary embodiments may attempt to account for more substantial deviations in a user's basal insulin needs and reduce or eliminate glucose level excursions that may result from such deviations more quickly than conventional insulin pump systems. The exemplary embodiments may rely upon a user's recent basal insulin delivery history to establish a current estimate of the user's basal insulin needs. Exemplary embodiments may calculate a reliability metric for a TDI value that reflects that degree of variance in TDI value for a user over a recent period, such as over multiple days or weeks. The reliability indicator may be used to adjust the TDI value that is used to establish a user's daily basal insulin needs and hourly basal insulin needs. In determining a user's basal insulin needs, the exemplary embodiments may not only look to recent basal insulin deliveries but also may account for correction boluses and / or meal boluses.
A continuous glucose monitor (CGM)-driven basal insulintitrationsystem and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulindose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulindose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.
A method of therapy upgrade for a diabetic patient includes: receiving glucose data of a user from an in vivo glucose monitoring device; receiving first therapy information for a first therapy, wherein the first therapy includes basal insulin; calculating one or more glucose metrics based on the received glucose data; titrating a dose of basal insulin based on the one or more glucose metrics; and determining a basal insulin excess based on one or more of the glucose data and the first therapy information. Advantageously, the system is capable of regularly monitoring a user's glucose control, detecting basal insulin excess, providing frequent therapy intervention and adjustments, reducing the duration of intervention, and improving user adherence, efficacy, and satisfaction.
Exemplary embodiments may attempt to account for more substantial deviations in a user's basal insulin needs and reduce or eliminate glucose level excursions that may result from such deviations more quickly than conventional insulin pump systems. The exemplary embodiments may rely upon a user's recent basal insulin delivery history to establish a current estimate of the user's basal insulin needs. Exemplary embodiments may calculate a reliability metric for a TDI value that reflects that degree of variance in TDI value for a user over a recent period, such as over multiple days or weeks. The reliability indicator may be used to adjust the TDI value that is used to establish a user's daily basal insulin needs and hourly basal insulin needs. In determining a user's basal insulin needs, the exemplary embodiments may not only look to recent basal insulin deliveries but also may account for correction boluses and / or meal boluses.
An apparatus comprising a user interface configured to generate an electrical signal to start a basal insulin rate test when prompted by a user, an input configured to receive sampled blood glucose data of a patient that is obtained during a specified time duration, including a time duration during delivery of insulin according to a specified basal insulin rate pattern, and a controller communicatively coupled to the input and the user interface. The controller includes an insulin calculation module configured for determining at least one of an amount of basal insulin over-delivered and an amount of basal insulin under-delivered during the basal insulin rate test in trying to meet a target blood glucose baseline. Other devices and methods are disclosed.
Presented is a medicament delivery system including a controller, a wearable medication delivery device, an analyte sensor, and other devices. In an example, a receiver is operable to receive glucose measurement values from the analyte sensor. A number of devices of the medicament delivery system may include a processor operable to execute programming code and to identify anomalous readings among the received glucose measurement values. The identified anomalous reading may, for example, be based on the received glucose measurement values violating a measurement change threshold indicative of abnormal sensor behavior. The processor may be operable to, in response to identifying the anomalous reading, revert a medicament delivery setting to a default safety basal delivery setting and / or generate a notification, an inquiry, and / or an alert for presentation to a user.
An insulin management method implemented by an insulin delivery device (130) is provided, where the insulin delivery device (130) is in the form of an automatic insulin delivery device that can be attached to the body of a user for the duration of a fasting period. The method includes delivering (152) insulin from an insulin delivery device (130) in the form of a corrected bolus dose of insulin in response to received blood glucose measurements during a fasting period over an entire period of time, where the insulin delivery device avoids administration of basal insulin at a preset or default rate or in a preset or default mode, where the insulin delivery device is coupled to the insulin delivery device (130) and the insulin delivery device (130) is coupled to the insulin delivery device (130) in the form of a corrected bolus dose of insulin during a fasting period over the entire period of time. During a non-fasting period over the entire time period, insulin is received by the user from a non-fasting insulin management modality (151), and the non-fasting insulin management modality provides at least one of a base dose of insulin and a bolus dose of insulin.
Exemplary embodiments may configure the glucose cost component of a cost function used in determining basal insulin delivery doses to be limited by the maximum physiological rate of glucose level change over a time period so that the cost function more accurately reflects the physical limits of change due to insulin action, As a result, the glucose cost component of the cost function may more accurately reflect the response of a user to basal insulin deliveries, resulting in better insulin control for the user. Exemplary embodiments may modify the aggressiveness of a control approach based on a current target glucose level versus a nominal target glucose level for which the control approach was designed.
The present disclosure relates to a diabetes managementsystem and methods related to the same. The system includes a pump device and a controller. The controller receives blood glucose data, determines basal insulin dosages based on stored baseline basal rates, controls insulin dispensation based on the determined basal insulin dosages, modifies a target blood glucose levels, receives a temporary override indicating a user preference to reduce the likelihood of a hypoglycemic or hyperglycemic event, determines a temporary target blood glucose level accordingly, and controls dispensation according to the temporary target blood glucose level. The controller can also calculate a probability that a blood glucose level crosses a threshold, determine a target blood glucose level based on a fear of hypoglycemia index and the calculated probability, determine insulin delivery information according to the target blood glucose level, and control dispensation accordingly.
A system for titrating a basal insulindose that includes a glucose monitoring device configured to collect glucose data of a user, processors in communication with the glucose monitoring device, and a memory coupled to the processors. The processors are configured to determine an initial basal insulindose, receive insulin data and glucose data during a titration period. The validity of each day is assessed, and a titration glucose level is determined for each valid day. The titration glucose level for each day is compared to glucose level thresholds, and a recommended adjustment to the basal insulindose is determined based on the comparison.
To provide a method for delivering blood glucose control in a subject having diabetes requiring such control.SOLUTION: Doses and dosing regimens are provided, comprising determining and administering doses of long-acting insulinreceptor agonists suitable for once-weekly dosing, such as Weekly Basal Insulin-Fc (BIF).SELECTED DRAWING: None
Determination of bolus doses of insulin and / or bolus doses and related systems, methods, and devices are disclosed. A method of determining a dietary bolus, a corrective bolus, and / or an underlying insulindose may include tracking a change in a carbohydrate ratio (CR) using a Q-learning algorithm, tracking a change in a correction factor (CF) using a nearest neighbor Q-learning algorithm, and determining a dietary bolus dose in response to the tracked CR and the tracked CF.
Provided are a method, system, and computer-readable medium for recommending titration measurement for basal insulin dosing and then automatedly causing delivery of the dosing. The recommendation can be personalized to accomplish a weekly recommended dosing according to evaluation for a daily titration glucose level (TGL) determined for received CGM data over the course of a preceding weekly time period. With increased receipt of CGM data, the TGLs can be categorized according to refinement for risk of occurrence of hypoglycemia, and the recommendation may be provided commensurately. In any instance, the recommendation can be automatedly adjusted either upon the CGM data satisfying conditions for hypoglycemia or upon a patient self-reporting hypoglycemia.